Eculizumab Dosing in Infants

Authors

M Kobrzynski, Western University
B Wile, Western University
S S Huang, Western University
G Filler, Western UniversityFollow

Document Type

Article

Publication Date

2-9-2018

Journal

Indian Journal of Nephrology

Volume

28

Issue

1

First Page

73

Last Page

75

URL with Digital Object Identifier

https://doi.org/10.4103/ijn.IJN_310_16

Abstract

Eculizumab is the therapy of choice for patients with atypical hemolytic uremic syndrome (aHUS). Dosing recommendations stem from two trials: one retrospective trial (19 children and 5 infants) and one prospective trial (22 patients and 5 infants). This case report highlights the need for more precise dosing recommendations in children, particularly in infants, and for smaller vials of the medication to facilitate more precise dosing. Such changes would ensure that adverse events are minimized and that the children with aHUS who are treated with eculizumab experience an optimal clinical response.

Notes

Article originally published in Indian Journal of Nephrology, Vol. 28(1).

Citation of this paper:

Kobrzynski M, Wile B, Huang S S, Filler G. Eculizumab dosing in infants. Indian J Nephrol 2018;28:73-5